Eli Lilly and Company’s Olumiant (baricitinib) has been recommended for approval in Europe for adolescents with severe ...
Atrium Therapeutics Inc. has launched as a newly independent, publicly traded company dedicated to delivering RNA therapeutics.
Discover how high-throughput antibody screening accelerates therapeutic and vaccine development, enabling faster biologics ...
WuXi XDC Cayman Inc. has entered a strategic collaboration with Earendil Labs on WuXi XDC's proprietary WuXiTecan-2 payload-linker technology platform.
Validogen is launching next-generation synthetic methanol-free promoters, which may lead to “substantially increased productivities.” ...
Boehringer Ingelheim has acquired an exclusive license for a preclinical, small molecule program from Sitryx Therapeutics.
SK bioscience, IDT Biologika, and Vaxxas will collaborate on a next-generation influenza vaccine development initiative.
Expands Quotient's capabilities for handling and manufacturing highly potent API (HPAPI) drug molecules and products.
Asahi Kasei has agreed to acquire all issued shares of Aicuris Anti-infective Cures AG, a German-based biopharmaceutical company.
Brainlab and Precision NeuroMed have a new strategic partnership for an artificial intelligence (AI)-enabled treatment planning platform.
Shilpa Biologicals has signed a licensing agreement with SteinCares to commercialize a biosimilar in the latter’s home region, Latin America.
How integrated pharmaceutical manufacturing helps CDMOs simplify scale-up, reduce complexity, and move from raw materials to finished dosage forms faster.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results